Skip to main content

Table 1 Parasite positivity according to day of follow up and continent

From: Early parasitological response following artemisinin-containing regimens: a critical review of the literature

 

Proportion of patients with patent parasitaemia

Parasite positivity rate

  

Number of study arms

Median %

[Range,IQR]

Africa

     

Day 1

53.2%

(6,694/12,576)

76

48.9%

[Range: 2.6-94.4 IQR: 26.6-66.4]

Day 2

8.3%

(1,575/19,044)

111

6.1%

[Range: 0–65.9, IQR: 1.6-11.2 ]

 

7.9%

(1,456/18,466)

107

6.0%

[Range: 0–65.9, IQR: 1.6-11.0 ]

Day 3

1.0%

(238/18,593)

115

0%

[Range: 0–36.5, IQR: 0–1.2 ]

 

1.0%

(176/17,223)

107

0%

[Range: 0–10.0, IQR: 0–1.2 ]

Asia

     

Day 1

59.0%

(2,794/4,733)

30

59.9%

[Range: 0—84.3, IQR: 37.7-74.0]

 

59.5%

(2,793/4,691)

28

61.6%

[Range: 16.4—84.3, IQR: 41.1-74.0]

Day 2

12.2%

(808/6,608)

45

8.9%

[Range: 0–72.5, IQR: 3.3-20.8]

Day 3

3.8%

(247/6,651)

45

1.1%

[Range: 0–55.0, IQR: 0–5.3]

 

3.8%

(243/6,399)

41

1.7%

[Range: 0–55.0, IQR: 0–5.6]

South America

     

Day 1

39.6%

(237/598)

5

48.0%

[Range: 32.3-75.0, IQR=41.5-48.0]

Day 2

6.0%

(43/719)

7

4.0%

[Range: 0–21.4, IQR=1.1-17.9]

Day 3

1.0%

(10/1044)

11

0%

[Range: 0–8.6, IQR=0-2.1]

  1. First row in each day category shows all reported results. The second row (if present) shows the results after exclusion of study arms with rectal artesunate and with short (<1, 2 or 3 days, respectively) treatment with artemisinin derivatives.